← Sichuan Kelun-Biotech overview

Sichuan Kelun-Biotech vs Replimune: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Sichuan Kelun-Biotech (6990.HK)

Q3 2026
▲4▼1

Kelun-Biotech's pipeline and sales advance, but bribery probe clouds the story

  • Lung-cancer combo succeeds in Phase III The sac-TMT plus pembrolizumab combo met its main goal in first-line PD-L1-negative non-squamous lung cancer — the first ADC-plus-immunotherapy Phase III win in this group. Success lifts hopes for a big new use of its flagship drug, supporting the stock.

    A major clinical win for the core drug is a key force behind the shares.

  • New dual-payload ADC enters clinic China's drug regulator cleared SKB565, the company's first dual-payload ADC, for human testing in advanced solid tumors. It is early-stage, but shows the pipeline keeps producing new candidates, which supports long-term growth expectations.

    Pipeline progress is a core driver of biotech valuation.

  • Bribery allegations create legal and reputational risk A whistleblower letter alleges commercial bribery tied to the company's flagship drug sac-TMT, naming hospitals in Beijing. Kelun-Biotech denies it and threatens legal action. If proven, fines or sales restrictions could hurt; even unproven, it dents trust.

    This is the main counterweight and a real risk to the stock.

  • Interim sales jump 112%, cash raised First-half product sales rose 112% to RMB 657 million, helped by insurance coverage for three sac-TMT uses and a new breast-cancer approval. The company also raised HK$2.72 billion in a share placing and dropped its 'B' marker, easing funding worries.

    Strong commercial execution and fresh capital directly support the shares.

  • Partner's asthma drug moves to Phase III Partner Windward Bio reported positive Phase 2 asthma results for SKB378/WIN378, showing lasting lung-function gains with twice-yearly dosing, and started Phase 3. Success could bring milestone payments and royalties, adding a new growth path beyond cancer.

    Partner validation of another pipeline asset is a fresh positive catalyst.

August 2026
▲4▼1

Kelun-Biotech's pipeline and sales advance, but bribery probe clouds the story

  • Lung-cancer combo succeeds in Phase III The sac-TMT plus pembrolizumab combo met its main goal in first-line PD-L1-negative non-squamous lung cancer — the first ADC-plus-immunotherapy Phase III win in this group. Success lifts hopes for a big new use of its flagship drug, supporting the stock.

    A major clinical win for the core drug is a key force behind the shares.

  • New dual-payload ADC enters clinic China's drug regulator cleared SKB565, the company's first dual-payload ADC, for human testing in advanced solid tumors. It is early-stage, but shows the pipeline keeps producing new candidates, which supports long-term growth expectations.

    Pipeline progress is a core driver of biotech valuation.

  • Bribery allegations create legal and reputational risk A whistleblower letter alleges commercial bribery tied to the company's flagship drug sac-TMT, naming hospitals in Beijing. Kelun-Biotech denies it and threatens legal action. If proven, fines or sales restrictions could hurt; even unproven, it dents trust.

    This is the main counterweight and a real risk to the stock.

  • Interim sales jump 112%, cash raised First-half product sales rose 112% to RMB 657 million, helped by insurance coverage for three sac-TMT uses and a new breast-cancer approval. The company also raised HK$2.72 billion in a share placing and dropped its 'B' marker, easing funding worries.

    Strong commercial execution and fresh capital directly support the shares.

  • Partner's asthma drug moves to Phase III Partner Windward Bio reported positive Phase 2 asthma results for SKB378/WIN378, showing lasting lung-function gains with twice-yearly dosing, and started Phase 3. Success could bring milestone payments and royalties, adding a new growth path beyond cancer.

    Partner validation of another pipeline asset is a fresh positive catalyst.

Latest
▲4▼1

Kelun-Biotech's pipeline and sales advance, but bribery probe clouds the story

  • Lung-cancer combo succeeds in Phase III The sac-TMT plus pembrolizumab combo met its main goal in first-line PD-L1-negative non-squamous lung cancer — the first ADC-plus-immunotherapy Phase III win in this group. Success lifts hopes for a big new use of its flagship drug, supporting the stock.

    A major clinical win for the core drug is a key force behind the shares.

  • New dual-payload ADC enters clinic China's drug regulator cleared SKB565, the company's first dual-payload ADC, for human testing in advanced solid tumors. It is early-stage, but shows the pipeline keeps producing new candidates, which supports long-term growth expectations.

    Pipeline progress is a core driver of biotech valuation.

  • Bribery allegations create legal and reputational risk A whistleblower letter alleges commercial bribery tied to the company's flagship drug sac-TMT, naming hospitals in Beijing. Kelun-Biotech denies it and threatens legal action. If proven, fines or sales restrictions could hurt; even unproven, it dents trust.

    This is the main counterweight and a real risk to the stock.

  • Interim sales jump 112%, cash raised First-half product sales rose 112% to RMB 657 million, helped by insurance coverage for three sac-TMT uses and a new breast-cancer approval. The company also raised HK$2.72 billion in a share placing and dropped its 'B' marker, easing funding worries.

    Strong commercial execution and fresh capital directly support the shares.

  • Partner's asthma drug moves to Phase III Partner Windward Bio reported positive Phase 2 asthma results for SKB378/WIN378, showing lasting lung-function gains with twice-yearly dosing, and started Phase 3. Success could bring milestone payments and royalties, adding a new growth path beyond cancer.

    Partner validation of another pipeline asset is a fresh positive catalyst.

Replimune Group Inc (REPL)

Q3 2026
▲2▼2

FDA panel backs RP1, approval and offering reshape Replimune

  • FDA panel backs RP1 An FDA advisory panel voted 10-3 that RP1's single-arm IGNYTE data were clinically meaningful, reversing earlier doubts and sending shares up over 130% premarket; Wedbush upgraded the stock.

    This was the key regulatory catalyst that drove the stock's massive jump.

  • Accelerated approval of Tudriqev The FDA granted accelerated approval to Tudriqev plus Opdivo for advanced melanoma (24.2% response rate), giving Replimune its first commercial product and revenue stream.

    This approval is a major milestone that transforms the company's business prospects.

  • Securities fraud investigations Two law firms (Kirby McInerney, Bragar Eagel & Squire) and later Pomerantz opened securities fraud investigations into whether the company misled investors before the FDA's critical July 28 briefing documents.

    These investigations pose a legal overhang that could weigh on the stock.

  • Dilutive stock offering A $150 million stock offering at $12.06/share issued ~9.7 million new shares, diluting existing holders.

    The offering dilutes current shareholders and can pressure the share price.

July 2026
▲2▼2

FDA panel backs RP1, approval and offering reshape Replimune

  • FDA panel backs RP1 An FDA advisory panel voted 10-3 that RP1's single-arm IGNYTE data were clinically meaningful, reversing earlier doubts and sending shares up over 130% premarket; Wedbush upgraded the stock.

    This was the key regulatory catalyst that drove the stock's massive jump.

  • Accelerated approval of Tudriqev The FDA granted accelerated approval to Tudriqev plus Opdivo for advanced melanoma (24.2% response rate), giving Replimune its first commercial product and revenue stream.

    This approval is a major milestone that transforms the company's business prospects.

  • Securities fraud investigations Two law firms (Kirby McInerney, Bragar Eagel & Squire) and later Pomerantz opened securities fraud investigations into whether the company misled investors before the FDA's critical July 28 briefing documents.

    These investigations pose a legal overhang that could weigh on the stock.

  • Dilutive stock offering A $150 million stock offering at $12.06/share issued ~9.7 million new shares, diluting existing holders.

    The offering dilutes current shareholders and can pressure the share price.

Latest
▲2▼2

FDA approves Replimune's first drug, then company raises $150M

  • FDA grants accelerated approval for Tudriqev The FDA granted accelerated approval to Replimune's Tudriqev combined with Opdivo for advanced melanoma, based on a 24.2% response rate. This is the company's first commercial product, turning it from a clinical-stage hopeful into a revenue-generating business and lifting the stock.

    This is the single biggest new event: approval validates the drug and opens a path to sales.

  • Securities fraud investigation expands to Pomerantz Pomerantz LLP opened an investigation into whether Replimune misled investors before the FDA's July 28 briefing documents questioned the RP1 data. This adds to earlier law firm probes, keeping a legal cloud over the stock and potentially weighing on the price.

    It is a new law firm joining the investigation, adding fresh negative pressure.

  • $150 million stock offering dilutes shareholders Replimune priced a $150 million stock sale at $12.06 per share, issuing about 9.7 million new shares. This raises cash to launch Tudriqev but dilutes existing investors' ownership, which typically pushes the stock down in the short term.

    It is a new financing event that directly affects share count and cash position.

  • FDA flexibility and biotech rally support Replimune The FDA signaled a more flexible approval approach for serious diseases, opening new pathways for Replimune and others. This supportive regulatory backdrop helped biotech stocks broadly and made RP1's eventual approval more likely, lifting sentiment around Replimune.

    It explains the favorable regulatory environment that helped Replimune's path to approval.

▲2▼1

FDA panel backs RP1, reversing prior briefing-document collapse

  • FDA advisory panel votes 10-3 in favor of RP1 An FDA advisory committee voted 10 to 3 that RP1's single-arm IGNYTE study results are evaluable and clinically meaningful for advanced melanoma. This removes the main regulatory doubt and makes approval by the August 2 target date far more likely, pushing the stock sharply higher.

    This is the core new event that flipped sentiment and drove the huge price jump.

  • Stock surges over 130% premarket, analyst upgrade Replimune shares soared more than 130% before the open and were up about 94-125% during the day after the panel vote. Wedbush upgraded the stock to outperform from neutral, a sign that professional investors now see the approval path as much clearer.

    Shows the market's immediate, large positive reaction and a key analyst endorsement.

  • Securities fraud investigations launched Two law firms, Kirby McInerney and Bragar Eagel & Squire, opened investigations into whether Replimune misled investors before the FDA's July 28 briefing documents called the RP1 study non-interpretable. No lawsuit has been filed yet, but this legal cloud could weigh on the stock.

    A real counterweight that could hurt the stock even after the positive panel vote.